Connect with us

Hi, what are you looking for?

Economy

World should not be complacent after COVID-19 vaccine news — WHO

Only very limited amounts of any vaccine will be available in the first half of 2021 for people other than priority health workers, World Health Organization officials said. Image via WHO/P. Virot

GENEVA — The World Health Organization (WHO) welcomed Moderna reporting on Monday that its experimental vaccine showed 94.5% efficacy but said that “many questions” remained and it was no time for complacency.

Only very limited amounts of any vaccine will be available in the first half of 2021 for people other than priority health workers, WHO officials said.

“While we continue to receive encouraging news about COVID-19 vaccines and remain cautiously optimistic about the potential for new tools to start to arrive in coming months, right now we are extremely concerned by the surge in cases we are seeing in some countries, particularly in Europe and the Americas,” WHO director-general Tedros Adhanom Ghebreyesus told a news briefing.

It marked his return to the Geneva agency from quarantine after being exposed to coronavirus some 17 days ago. Tedros said he had no symptoms and had seen no need for a test.

Moderna Inc.’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second US drugmaker to report results that far exceed expectations.

Together with Pfizer Inc’s vaccine, which is also more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available this year.

Soumya Swaminathan, WHO’s chief scientist, said that the Moderna results were “quite encouraging.” Its final efficacy and safety profile would still be needed, as well as follow-up on trial participants for two months for any side effects.

Pfizer and Moderna candidate vaccines both use mRNA technology and appear to achieve high efficacy, she added.

“But there are many, many questions still remaining about the duration of protection, the impact on severe disease, the impact on different sub-populations especially the elderly, as well as the adverse events beyond a certain period of time,” Ms. Swaminathan said.

Clinical trials must continue to collect more data, she said, adding that more results were expected in coming weeks from the other vaccine trials.

“We are looking at at least the first half of the year as being a period with very very limited doses. Supplies are going to be limited, there are bilateral deals that many of the companies have done, so many of the doses have already been booked by some countries,” Ms. Swaminathan said.

Moderna is a two-dose vaccine and its delivery means, as well as storage, were also important considerations, said Kate O’Brien, director of WHO’s immunization department.

“We will be looking really carefully at the ease at which different vaccines can be delivered and certainly about the number of doses that are required,” she said. — Stephanie Nebehay and Emma Farge/Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

THE DEPARTMENT of Public Works and Highways (DPWH) said Tuesday that it will support local government units (LGUs) and map out a clear division...

Economy

A TOTAL of 4.73 million coronavirus vaccine doses procured under a World Bank loan have arrived in the Philippines, the bank said. Over eight...

Economy

THREE INDIVIDUALS filed a complaint before the Office of the Ombudsman against Energy Secretary Alfonso G. Cusi and other officials, alleging corruption in connection...

Economy

A NON-GOVERNMENT organization (NGO) urged candidates running for President to reveal their views on how they plan to govern with borrowed money. Freedom from...

Economy

THE BOARD of Investments (BoI) said it recently approved an application for incentives of Libertad Power and Energy Corp. for a 6-megawatt (MW) biomass...

Economy

THE DEPARTMENT of Agriculture (DA) lifted a ban on cattle imports from Brazil after a finding that cattle from that country have a negligible...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Economy

Pfizer Inc on Wednesday raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion, and said it believes people will...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.



Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!